A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/16 (2006.01) A61K 38/00 (2006.01) A61K 38/18 (2006.01) A61K 39/395 (2006.01) A61P 25/28 (2006.01)
Patent
CA 2485216
The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via PACAP, Maxadilan or VIP signaling. These methods are useful for reducing at least one symptom of the disorder.
L'invention concerne d'une manière générale des procédés pour influencer les cellules du système nerveux central afin de produire une progéniture utile dans le traitement de troubles du SNC. Elle concerne plus particulièrement des procédés pour exposer un patient souffrant d'un de ces troubles à un réactif qui module la prolifération, la migration, la différentiation et la survie des cellules du système nerveux central via la signalisation PACAP, Maxadilan ou VIP. Ces procédés sont utiles pour réduire au moins un symptôme du trouble en question.
Mercer Alex
Patrone Cesare
Roennholm Harriet
Wikstroem Lilian
Neuronova Ab
Ridout & Maybee Llp
LandOfFree
Therapeutic use of pacap, maxadilan, pacap receptor agonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of pacap, maxadilan, pacap receptor agonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of pacap, maxadilan, pacap receptor agonist... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1380620